30 completed, 14 terminated, 5 recruiting, 4 unknown. 26 Phase 1, 20 Phase 2, 9 Not applicable, 7 Phase 3, 1 Phase 4.
Follow Non-Small Cell Lung Carcinoma: new trials by email Literature Review of Non-Small Cell Lung Carcinoma trials Research Report on Non-Small Cell Lung Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) azacytidine, carboplatin, paclitaxel - Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung | Phase 1 / Phase 2 | Suspended | National Cancer Institute (NCI) | 60 | 2026-10-28 | 2026-10-23 |
| Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer Montanide (Registered Trademark) ISA-51 VG Adjuvant, H1299 Cell Lysates, N-803 - Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma | Phase 1 / Phase 2 | Suspended | National Cancer Institute (NCI) | 30 | 2026-10-28 | 2026-10-23 |
| BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) BPI-361175 - Non-small Cell Lung Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Xcovery Holdings, Inc. | 30 | 2026-07-01 | 2025-10-07 |
| First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors PLX-61639 - Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma | Phase 1 | Recruiting | Plexium, Inc. | 155 | 2025-12-01 | 2026-06-12 |
| A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC) PF-08046054, Docetaxel monotherapy - Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic | Phase 3 | Recruiting | Pfizer | 680 | 2025-09-29 | 2026-10-13 |
| Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT 89Zr-Patritumab deruxtecan - Non-Small Cell Lung Carcinoma, Advanced Non-Small Cell Squamous Lung Cancer | Phase 2 | Recruiting | The Netherlands Cancer Institute | 16 | 2025-03-03 | 2026-08-10 |
| A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation PRT7732 - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Terminated | Prelude Therapeutics Incorporated | 42 | 2024-11-04 | 2026-02-02 |
| Study of IK-595 in RAS- or RAF-altered Advanced Tumors IK-595 - Solid Tumor, Adult, Colorectal Cancer | Phase 1 | Terminated | Ikena Oncology | 75 | 2023-12-18 | 2025-09-19 |
| Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation JDQ443, trametinib, Ribociclib - KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung | Phase 1 / Phase 2 | Terminated | Novartis Pharmaceuticals | 74 | 2022-10-24 | 2026-10-21 |
| Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC. Capmatinib 150 mg, Capmatinib 200 mg - Non-Small Cell Lung Carcinoma | Phase 4 | Completed | Novartis Pharmaceuticals | 50 | 2022-09-03 | 2026-10-02 |
| NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC efineptakin alfa, Atezolizumab - Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer | Phase 2 | Terminated | NeoImmuneTech | 33 | 2021-11-15 | 2026-06-11 |
| Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery Light Dosimetry for Intranoperative Therapy, Photodynamic Therapy, Porfimer Sodium - Malignant Mesothelioma, Non-Small Cell Lung Carcinoma | Phase 1 | Completed | Roswell Park Cancer Institute | 9 | 2021-09-17 | 2026-03-27 |
| Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection Almonertinib, Pemetrexed, Cisplatin - Non-small Cell Lung Carcinoma | Phase 3 | Enrolling by invitation | Chinese Academy of Medical Sciences | 606 | 2021-08-01 | 2022-02-24 |
| To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy Drug: Furmonertinib 80 mg, Furmonertinib 80 mg placebo - Non-small Cell Lung Carcinoma | Phase 3 | Recruiting | Allist Pharmaceuticals, Inc. | 318 | 2021-06-07 | 2026-08-13 |
| The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) rezatapopt, pembrolizumab - Advanced Solid Tumor, Advanced Malignant Neoplasm | Phase 1 / Phase 2 | Recruiting | PMV Pharmaceuticals, Inc | 300 | 2020-10-29 | 2026-10-02 |
| NEUWAVE Flexible Probe Study #2 Microwave ablation - Cancer of the Lung, Lung Cancer | Not applicable | Withdrawn | Ethicon, Inc. | 2020-07-31 | 2020-06-02 | |
| A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled Lorlatinib - Non-Small Cell Lung Carcinoma | Completed | Pfizer | 73 | 2020-07-22 | 2026-03-10 | |
| Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer Porfimer Sodium, Ultrasound-Guided Transbronchial Needle-Delivered Interstitial Photodynamic Therapy - Locally Advanced Lung Carcinoma, Non-Small Cell Lung Carcinoma | Phase 1 / Phase 2 | Completed | Roswell Park Cancer Institute | 19 | 2020-02-12 | 2026-05-14 |
| DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer Trastuzumab deruxtecan (DS-8201a), Pembrolizumab - Breast Cancer, Non-small Cell Lung Carcinoma | Phase 1 | Active not recruiting | Daiichi Sankyo | 115 | 2020-02-10 | 2025-11-18 |
| Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies TNO155, Spartalizumab, Ribociclib - Non-small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma | Phase 1 | Terminated | Novartis Pharmaceuticals | 122 | 2019-07-30 | 2025-09-30 |
Showing 20 of 63. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (63) · Lung Neoplasms (12) · Colorectal Neoplasms (11) · Melanoma (10) · Small Cell Lung Carcinoma (9) · Breast Neoplasms (8) · Carcinoma, Renal Cell (8) · Prostatic Neoplasms (7) · Squamous Cell Carcinoma of Head and Neck (7) · Pancreatic Neoplasms (6) · Carcinoma, Transitional Cell (5) · Neoplasm Metastasis (5) · Ovarian Neoplasms (5) · Triple Negative Breast Neoplasms (5) · Carcinoma, Hepatocellular (4)
Carcinoma, Bronchogenic (63) · Lung Diseases (63) · Neoplasms by Site (63) · Respiratory Tract Diseases (63) · Respiratory Tract Neoplasms (63) · Thoracic Neoplasms (63) · Bronchial Neoplasms (62) · Neoplasms (61) · Lung Neoplasms (51) · Neoplasms by Histologic Type (21) · Neoplasms, Glandular and Epithelial (21) · Digestive System Diseases (17) · Gastrointestinal Diseases (17) · Digestive System Neoplasms (16) · Gastrointestinal Neoplasms (16)
pembrolizumab (9) · Carboplatin (7) · Paclitaxel (7) · Cisplatin (5) · Docetaxel (5) · Pemetrexed (5) · Gemcitabine (4) · AM0010 (2) · Afatinib (2) · Albumin-Bound Paclitaxel (2) · Dihematoporphyrin Ether (2) · Erlotinib Hydrochloride (2) · Ipilimumab (2) · Radiotherapy (2) · pegilodecakin (2)
Merck Sharp & Dohme LLC (3) · Novartis Pharmaceuticals (3) · Xencor, Inc. (3) · Daiichi Sankyo (2) · Eli Lilly and Company (2) · National Cancer Institute (NCI) (2) · Pfizer (2) · Roswell Park Cancer Institute (2) · Seagen Inc. (2) · University of Texas Southwestern Medical Center (2) · Vanderbilt-Ingram Cancer Center (2) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Allist Pharmaceuticals, Inc. (1) · Astellas Pharma Inc (1) · Celgene (1)
United States (39) · France (7) · Germany (7) · Spain (7) · Belgium (5) · China (5) · South Korea (5) · Australia (4) · Canada (4) · Italy (4) · Netherlands (4) · United Kingdom (4) · Israel (3) · Japan (3) · Singapore (3)
David S Schrump, M.D. (2) · Alfred Zippelius, Prof. Dr. (1) · Benjamin Thompson, MD, PhD (1) · Caroline Germa, MD (1) · Chet Bohac, MD, MSc (1) · Christine Collen, MD (1) · David E Gerber, MD (1) · David Gerber (1) · Donghoon Choi, PhD (1)
PMID 12704670, PMID 22547591, PMID 23123509, PMID 23545279, PMID 23842283, PMID 24346096, PMID 25288198, PMID 26104945, PMID 26811178, PMID 27528724, PMID 27718847, PMID 27745820, PMID 28689056, PMID 29129441, PMID 30138764, PMID 30274964, PMID 30429032, PMID 30529597, PMID 30606144, PMID 30736848, PMID 31075217, PMID 31395089, PMID 31563517, PMID 31865308, PMID 31880807, PMID 32000810, PMID 32305010, PMID 32926507, PMID 33433743, PMID 33830168, PMID 33872070, PMID 33985811, PMID 34323922, PMID 34543477, PMID 34663123, PMID 34842538, PMID 35073727, PMID 36969745, PMID 37219548, PMID 37465924, PMID 37562791, PMID 37922432, PMID 40543428, PMID 40932470, PMID 41740031
2014 (1), 2016 (1), 2018 (1), 2023 (1), 2025 (1), P30CA014089 (1), P30CA015083 (1), R44CA265656 (1), U10CA180868 (1)